Cover Image

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Abstract Bruton's tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B‐cell receptor and Fc‐receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, re...

Full description

Saved in:
Bibliographic Details
Main Authors: Timothy D. Owens (Author), Patrick F. Smith (Author), Andrew Redfern (Author), Yan Xing (Author), Jin Shu (Author), Dane E. Karr (Author), Sonja Hartmann (Author), Michelle R. Francesco (Author), Claire L. Langrish (Author), Philip A. Nunn (Author), Steven G. Gourlay (Author)
Format: Book
Published: Wiley, 2022-02-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items